The central biobank and virtual biobank of BIOMARKAPD: a resource for studies on neurodegenerative diseases

Frontiers in Neurology

Tormod eFladby¹  Magda eTsolaki²  Sylvain eLehmann³  Frederic eBrosseron⁴  Alberto eLleó⁵  Nikolai eGoncharenko⁶  Fay eBetsou⁶  José Luis eMolinuevo⁷  Enrica eCavedo⁸  Fabrizio eTagliavini⁹  Hakan eGurvit^1,10  Bengt eWinblad^1,11  Frans R Verhey^1,12  Babette eReijs^1,12  Tomasz eGabryelewicz^1,13  Elisabeth eKapaki^1,14  Brit eMollenhauer^1,15  Marcel M Verbeek^1,16  Anja Hviid Simonsen^1,17  Kaj eBlennow^1,18  Anne-Marie eMiller^1,19  Peter eKoson^2,20  Anja eSchneider^2,21  Uros eRot^2,22  Inês eBaldeiras^2,23  Lutz eFroelich^2,24  Alexandre ede Mendonça^2,25  Lucilla eParnetti^2,26  Walter eMaetzler^2,27  Luka eKulic^2,28  Piotr eLewczuk^2,29  Charlotte Elisabeth Teunissen^3,30  Philip eScheltens^3,31  Pieter Jelle eVisser^3,31  Marzena eZboch^3,32  Henrik eZetterberg^3,33 

[1] Akershus University Hospital;Aristotle University of Thessaloniki;CHRU de Montpellier, Université de Montpellier and INSERM U1183;German Center for Neurodegenerative Diseases (DZNE) e.V. Clinical Neuroscience and Biomarkers;Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau;IBBL (Integrated Biobank of Luxembourg);ICN Hospital Clinic i Universitari and Pasqual Maragall Foundation;IRCCS Fatebenefratelli;IRCCS Foundation Carlo Besta Neurological Institute;Istanbul University;Karolinska Institutet;Maastricht University Medical Centre;Mossakowski Medical Research Centre Polish Academy of Sciences;National and Kapodistrian University of Athens;Paracelsus-Elena-Klinik;Radboud University Medical Centre;Rigshospitalet, Copenhagen University Hospital;The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital;Trinity College Dublin;University Hospital Bratislava;University Medical Center Göttingen ;University Medical Centre;University of Coimbra;University of Heidelberg;University of Lisbon;University of Perugia;University of Tübingen;University of Zurich;Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg;VU University Medical Center Amsterdam;VU University Medical Centre;Wrocław Medical University;the Sahlgrenska Academy at the University of Gothenburg;

关键词: Body Fluids;    Cerebrospinal Fluid;    Dementia;    Neurodegenerative disorders;    Alzheimer's disease (AD);    Biobank;   

DOI  :  10.3389/fneur.2015.00216

来源: DOAJ

【 摘 要 】

AbstractBiobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's Disease (BIOMARKAPD) is a European multicenter study, funded by the EU Joint Programme - Neurodegenerative Disease Research (JPND), that aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer’s disease (AD) and Parkinson’s disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized preanalytical procedures (SOP) and stored at Integrated BioBank of Luxembourg (IBBL).The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia (VaD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), PD, PD with dementia, and dementia with Lewy bodies (DLB). The virtual biobank contains information on over 8600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.

【 授权许可】

Unknown